C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice

Influenza A H1N1 infection can trigger severe inflammatory responses that contribute to pulmonary tissue injury and disease progression. Aberrant complement activation is presumed to contribute to these pathological changes. Nevertheless, it remains unclear whether complement C3 serves as a shared upstream regulatory node linking inflammation and hemolytic injury. In this study, we established an H1N1-infected mouse model to dynamically monitor changes in inflammation, hemolysis and complement-related parameters throughout infection. We evaluated the C3-silencing efficacy of RG002, a liver-targeted siRNA against complement C3, as well as the therapeutic efficacy of RG002 combined with oseltamivir against H1N1 infection. Our results showed that H1N1 infection induced prominent inflammatory responses and alterations in peripheral blood cell parameters, accompanied by pulmonary histopathological injury in mice. Hepatic C3 expression and complement activity were simultaneously and markedly elevated. RG002 suppressed C3 expression in a dose-and time-dependent manner and reduced complement-mediated erythrocyte lysis in serum. In vivo therapeutic experiments demonstrated that on the basis of viral replication suppression achieved by oseltamivir, combination treatment with RG002 inhibited excessive complement activation. This combined regimen reduced pro-inflammatory cytokine levels, attenuated pulmonary histopathological injury, and improved selected peripheral blood cell parameters. Notably the low-dose RG002 combination group exhibited superior performance across multiple evaluation indices, suggesting that the degree of C3 suppression is preferable to influence therapeutic effucaty. Collectively, our findings implicate complement C3 in the inflammatory pathology associated with H1N1 infection and demonstrate the therapeutic potential of C3-targeting siRNA as an adjunct to antiviral treatment. This study provides experimental evidence supporting the combination of antiviral therapy and controlled complement modulation as a potential host-directed therapeutic strategy for severe influenza.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.16.766876
Primary Topic
Influenza Virus Research Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice

Yuanyu Huang, Qi Ma, Yuhua Weng, Baoying Huang et al.
bioRxiv (Cold Spring Harbor Laboratory)
Influenza Virus Research Studies
preprint

C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice

Yuanyu Huang, Qi Ma, Yuhua Weng, Baoying Huang, Li Haitao, Yu Li, Xinyu Gao, Zimu Li, Jinchao Zhang, Minghui Yang, Yu Ou, Yizheng Ao, Yawei Wang, Xing-Jie Liang, Haoyuan Feng, gege Shi, Xiaofeng Han, Zixin Tu, Shangqing Gao
preprint en

Abstract

Influenza A H1N1 infection can trigger severe inflammatory responses that contribute to pulmonary tissue injury and disease progression. Aberrant complement activation is presumed to contribute to these pathological changes. Nevertheless, it remains unclear whether complement C3 serves as a shared upstream regulatory node linking inflammation and hemolytic injury. In this study, we established an H1N1-infected mouse model to dynamically monitor changes in inflammation, hemolysis and complement-related parameters throughout infection. We evaluated the C3-silencing efficacy of RG002, a liver-targeted siRNA against complement C3, as well as the therapeutic efficacy of RG002 combined with oseltamivir against H1N1 infection. Our results showed that H1N1 infection induced prominent inflammatory responses and alterations in peripheral blood cell parameters, accompanied by pulmonary histopathological injury in mice. Hepatic C3 expression and complement activity were simultaneously and markedly elevated. RG002 suppressed C3 expression in a dose-and time-dependent manner and reduced complement-mediated erythrocyte lysis in serum. In vivo therapeutic experiments demonstrated that on the basis of viral replication suppression achieved by oseltamivir, combination treatment with RG002 inhibited excessive complement activation. This combined regimen reduced pro-inflammatory cytokine levels, attenuated pulmonary histopathological injury, and improved selected peripheral blood cell parameters. Notably the low-dose RG002 combination group exhibited superior performance across multiple evaluation indices, suggesting that the degree of C3 suppression is preferable to influence therapeutic effucaty. Collectively, our findings implicate complement C3 in the inflammatory pathology associated with H1N1 infection and demonstrate the therapeutic potential of C3-targeting siRNA as an adjunct to antiviral treatment. This study provides experimental evidence supporting the combination of antiviral therapy and controlled complement modulation as a potential host-directed therapeutic strategy for severe influenza.

bioRxiv (Cold Spring Harbor Laboratory)
Beijing Institute of Technology (CN), National Institute for Viral Disease Control and Prevention (CN), National Center for Nanoscience and Technology (CN), Hebei University (CN)
Beijing Institute of Technology
Good health and well-being
Influenza Virus Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon